Company Analysis
Sign in

Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · Pharmaceutical Preparations · Tokyo, JP · filing with the SEC since 2007
Full chart Alerts Compare
Grade5.7
◀ Past 7.8● Present 4.9▶ Future 4.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1,182 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Takeda Pharmaceutical Company Limited’s names, not what it holds today.

Patents granted
1,182
1,158 utility, 21 design, 3 reissue, 1976 to Dec 31, 2025
Granted in 2025
90
Against 76 in 2024 and 70 in 2023
Applications published
1,371
86 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals173
Organic fine chemistry68
Biotechnology34
Medical technology17
Analysis of biological materials12
Chemical engineering7
Computer technology5
Measurement4
Basic materials chemistry2
Handling1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Takeda Pharmaceutical Company Limited its own name
JP, as the owner printed on each patent. 12 more under the same name are not counted (printed in US, printed in GB)
1,182 granted
873 published
Takeda Pharmaceutical Company Limited its own name
named as the applicant on its applications, in JP. 13 more under the same name are not counted (printed in US)
0 granted
498 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,501Treatment of central nervous system disorders by intranasal administration of immunoglobulin GPharmaceuticalsTakeda Pharmaceutical Company Limited
Dec 9, 202512,493,047Cleaved high molecule weight kininogen (HMWK) antibodies and methods of usingAnalysis of biological materialsTakeda Pharmaceutical Company Limited
Dec 9, 202512,492,390Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereofBiotechnologyTakeda Pharmaceutical Company Limited
Nov 25, 2025D1,103,202Display screen or portion thereof with graphical user interfaceTakeda Pharmaceutical Company Limited
Nov 25, 202512,479,798Method for producing pyrrolidine compoundOrganic fine chemistryTakeda Pharmaceutical Company Limited
Nov 25, 202512,479,791Cationic lipidOrganic fine chemistryTakeda Pharmaceutical Company Limited
Nov 25, 202512,478,673Constrained conditionally activated binding proteinsBiotechnologyTakeda Pharmaceutical Company Limited
Nov 11, 2025D1,101,762Display screen with a transitional graphical user interfaceTakeda Pharmaceutical Company Limited
Nov 4, 202512,460,016Plasma kallikrein binding proteinsPharmaceuticalsTakeda Pharmaceutical Company Limited
Oct 28, 202512,454,575Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodiesPharmaceuticalsTakeda Pharmaceutical Company Limited
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387455TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWFPharmaceuticalsTakeda Pharmaceutical Company Limited
Dec 18, 20252025/0382574CELL CULTURE METHODPharmaceuticalsTakeda Pharmaceutical Company Limited
Dec 18, 20252025/0381339VOLUME ESTIMATION FOR INFUSION PUMPMeasurementTakeda Pharmaceutical Company Limited
Dec 18, 20252025/0381338INFUSION PUMP SYSTEMMedical technologyTakeda Pharmaceutical Company Limited
Dec 11, 20252025/0375506CNS DELIVERY OF THERAPEUTIC AGENTSPharmaceuticalsTakeda Pharmaceutical Company Limited
Dec 11, 20252025/0375417OREXIN RECEPTOR 2 (OX2R) AGONIST FOR USE IN NARCOLEPSY TYPE 1 (NT1)PharmaceuticalsTakeda Pharmaceutical Company Limited
Dec 11, 20252025/0374917COMPOSITIONS AND METHODS OF CRYOPRESERVING CELLSBasic materials chemistryTakeda Pharmaceutical Company Limited
Dec 4, 20252025/0368660Thienopyrimidine derivativeOrganic fine chemistryTakeda Pharmaceutical Company Limited
Nov 20, 20252025/0354114METHODS OF PRODUCING ENGINEERED IMMUNE CELLSPharmaceuticalsTakeda Pharmaceutical Company Limited
Nov 20, 20252025/0353923ANTI-CD38 FUSION PROTEIN FORMULATIONPharmaceuticalsTakeda Pharmaceutical Company Limited
What it applied for, 2024 to 2025: Pharmaceuticals 94 · Biotechnology 36 · Organic fine chemistry 23 · Medical technology 16 · Analysis of biological materials 5 · Computer technology 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TAK · research, not advice